Siemens Healthineers: A 13% Gap Between Price and Analyst Targets, With a Spin-Off Looming

Siemens Healthineers trades 13% below analyst targets despite 15% monthly rebound; mixed Q3 results and tax-free spin-off clarity shape outlook.

The arithmetic is straightforward, yet the market's verdict remains unsettled. Siemens Healthineers trades at roughly €39.86, while the average analyst price target sits at €44.99 — a gap of about 13 percent that investors will be debating in the weeks ahead. The stock's recent momentum suggests some are betting on convergence; the company's own guidance revisions suggest others are waiting for proof.

That momentum is real enough. On a 30-day basis, the shares have climbed 15 percent, and the stock closed Wednesday at €40.14 after a 2.0 percent daily gain. The rebound has lifted the equity well off its 52-week low of €32.84, a level touched only in May. Yet the longer-term picture remains sobering: the shares are still down 11 percent year-to-date and 17 percent over the past twelve months, with roughly 19 percent of upside needed to reclaim the 52-week high of €49.78 set last October.

A Mixed Earnings Picture

The disconnect between short-term strength and longer-term underperformance traces back to the company's third-quarter results, released on July 31, 2026. Net income rose to €676 million, or €0.60 per share, up from €556 million in the prior-year quarter. On an adjusted basis, earnings per share came in at €0.70, a figure that includes a notable special item: refunds related to US tariffs.

Revenue grew 2.8 percent to €5.76 billion, with the EMEA region providing the primary lift. But the outlook accompanying those numbers was decidedly two-sided. Management trimmed its full-year revenue growth forecast to 3.5 to 4.0 percent, down from a prior range of 4.5 to 5.0 percent, citing persistent weakness in the diagnostics business. Reuters has pointed to China's procurement policies and the ongoing migration to a new laboratory platform as the specific drags.

At the same time, the company raised its adjusted earnings guidance to €2.35 to €2.45 per share, up from €2.20 to €2.30. The entire increase, however, stems from those tariff refunds — a €0.15 per share effect. Operationally, the improvement is modest at best, which helps explain why the stock has not fully recovered its earlier losses.

Buybacks and the Spin-Off Factor

Against that backdrop, Siemens Healthineers continues to execute its share repurchase program with notable consistency. The company announced Monday the acquisition of another 50,000 of its own shares between August 10 and 16, bringing the total bought back since the program began on June 1 to 2,824,371 shares.

The buyback's steady cadence contrasts with the operational noise, but another development may carry more weight for the share price. Reuters reported in early August that parent company Siemens has reached an agreement with German tax authorities on a tax-free structure for the planned distribution of Healthineers shares to Siemens shareholders. That clarity removed a significant overhang from the spin-off process and likely contributed to the firmer tone in the stock.

Analysts Split on the Path Forward

The analyst community remains divided on what comes next. JPMorgan upgraded the stock to "Overweight" in early August with a price target of €57.40 — by far the most bullish call on the Street. Deutsche Bank struck a more cautious note on Tuesday, raising its target from €38 to €39 while keeping a "Hold" rating.

The wide dispersion in targets reflects genuine uncertainty about the diagnostics recovery timeline. JPMorgan appears to anticipate a relatively swift stabilization; Deutsche Bank sees operational challenges that have yet to be fully resolved.

For the current fiscal year, consensus estimates put earnings per share at €2.36, with analysts expecting a dividend of €1.03 per share, up from €1.00 in 2025. The stock currently trades about 2 percent above its 200-day moving average of €39.11 — a sign of a medium-term uptrend that has not yet become overheated.

The next scheduled report arrives on November 5, 2026. By then, investors will have a clearer read on whether the summer's reduced growth forecast holds or whether diagnostics rebounds faster than expected. That report will also test whether the gap to the average price target represents an opportunity or a warning — and whether the buyback and spin-off momentum can offset the operational headwinds in the meantime.